Faeth Therapeutics Reports Third-Quarter Net Loss of $20.4 Million
Faeth reported a $20.4 million net loss for the third quarter of 2026, compared with a $4.6 million loss a year earlier. Basic and diluted loss per share narrowed to $0.79 from $3.62.
Faeth Therapeutics reported a net loss of $20.4 million for the third quarter of 2026, compared with a $4.6 million loss a year earlier. Basic and diluted loss per share narrowed to $0.79 from $3.62.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Faeth Therapeutics, Inc. [ FTH ] - 10-Q…